“My colleagues and I are amazed by the curative effect of hemoperfusion. Since being treated with that blood purification therapy, the patients have reduced their dependence on medication, and their physical conditions are improving, too,” said Dr. Fernando from Castellón, Spain. “We think that its therapeutic options in intensive care are multiple, and among all adopters of this technology we will be able to create new evidence in favor of the use of this device.”

Jafron attaches great importance to Spain as it has one of the most advanced health care systems in the world. Since entering the Spanish market in 2020, Jafron’s therapies have been implemented at several hospitals in five provinces: Madrid, Barcelona, Zaragoza, Cartagena, and Castellón.

In addition, newly successful treatment cases offer doctors great confidence and new weapon with adsorption technologies. After joining the study of hemoperfusion applications, Prof. José Angel Sánchez Izquierdo from Hospital Universitario 12 de Octubre, the head of polyvalent section of ICU Department, implemented this technology in liver failure patients. After two-week treatment, he was completely satisfied with the results.

Dr. María Galindo from the central hospital in Cartagena, Murcia province, was also impressed with the novel hemadsorption treatment. After experiencing its implementation on a patient for 12 hours, she is happy to feedback that it is one of the promising technologies for blood purification, and it also minimizes the risk of blood coagulation.

All doctors’ and experts’ feedback has given the medical society awareness of adsorption and built their confidence in its application. Meanwhile, guiding the western European community to use adsorption therapy seriously and scientifically is one of its most important strategies of Jafron. Over the past years, it has organized many training courses and international forums on hemoperfusion and blood purification techniques in treating various diseases. And for the future, the company will continue to be present at international conferences and launch more online courses to advance doctors’ perceptions.

In October, Jafron will attend the 35th ESICM in Europe with its original developed technology and complete portfolio of adsorption therapies. Such as, HA60 hemoperfusion cartridge and BS80 Disposable Plasma Bilirubin Perfusion Adsorption Column for low body weight patients, HA130 hemoperfusion therapy for ESRD complications, JF-800A and Future F20 hemoperfusion Machine, etc.

Caroline Jin, the vice president of Jafron, is leading the international team to keep moving forward with our strategic pillars for globalization, including global infrastructure and platform, global market service, global portfolio and therapy offering, as well as global connection and alliance.

Indeed, there is a long way to go for hemoperfusion therapy to be more standard and well-studied. But Jafron is still heading towards the encouraging journey to serving our patients worldwide with adsorption technologies and extracorporeal treatments, alleviating their suffering and saving their lives.